Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · aTYR PHARMA INC (ATYR)

aTyr Pharma files prospectus for up to $79,994,251 in stock sales via Jefferies

Neutral Impact 2 of 5 financing

aTyr Pharma filed a prospectus supplement allowing it to sell common stock worth up to $79,994,251 from time to time under an existing open market sale agreement with Jefferies LLC. The filing sets up potential share issuance that could dilute existing shareholders, though the filing does not state how much stock has been or will be sold.

Key points

  • Maximum aggregate offering price of up to $79,994,251 under the Sales Agreement with Jefferies LLC, dated April 22, 2022, as amended December 23, 2024
  • Offering is made under Form S-3 shelf registration (File No. 333-289360), filed August 7, 2025 and declared effective August 18, 2025
  • Cooley LLP legal opinion on the legality of the shares filed as Exhibit 5.1

The filing

CompanyaTYR PHARMA INC (ATYR)
Form8-K, current report
Filed with the SECNov 6, 2026, 4:08 PM ET
Accession number0001339970-26-000085

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.